Score Your Stock

US stock · figures in US dollars · scored on full-year results

ResMed ResMed Inc. Common Stock

RMD · Healthcare · Medical Instruments & Supplies
Top 4% of scored stocks
OkayTop 4% of scored stocks
Weak Spot

ResMed scores 77/100 on fundamentals: in the top 4% of 503 scored S&P 500 stocks. Its strongest area is Business Strength (100/100); its weakest is Price Fairness (17/100). It carries 1 warning flag: Weak Spot.

Best
Business 100
Financial 100
Weakest
Price 17
  • Carries a Weak Spot flag

A financially strong, expensively priced stock with healthy growth, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 32.3b#310 of 503 in the S&P 500EPSUS$ 10.43P/E21.8×✓ vs sector median 30.5×P/B5×✗ vs sector median 3.7×Div yield1%Bottom 44% in the S&P 50052w range · 51% of range180.27277.67
as of 31 Oct 2026

Nearby peers

Ranks #2 of 60 in Healthcare by score

#1Universal Health Services79
#2ResMed77
#3Steris75#4Dexcom73#5Insulet71#6Boston Scientific68

One-Minute Summary

Why ResMed scores 77

A financially strong, expensively priced stock with healthy growth, but price fairness needs attention.

What looks good
What to watch

Business Strength

100
Why 100?
Pillar score: (2 + 2 + 2 + 2 + 2) = 10 of 10 points → 100
Return on Equity (ROE)23%Strong4-Year Revenue Growth+10%/yrStrong4-Year Profit Growth+19%/yrStrongNet Profit Margin27%StrongQuarterly Momentum+10%Strong
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↑ +69.7%Equity ↑ +59.5%ROE % 23.1%
Net ProfitEquityROE %
898m1.0b1.4b1.5b4.1b4.9b6.0b6.6b202320242025202621.7%21%23.5%23.1%

Revenue & Net Profit, with Net Margin

Revenue ↑ +33.9%Net Profit ↑ +69.7%Net Margin % 26.9%
RevenueNet ProfitNet Margin %
4.2b4.7b5.1b5.7b898m1.0b1.4b1.5b202320242025202621.3%21.8%27.2%26.9%

Sales grew about 33.9% over 4 years: customers keep spending more with this company.

Profit climbed about 69.7% over 4 years: the business keeps more money as it grows.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +19.5%Net Profit ↑ +23.1%Net Margin % 26.2%
RevenueNet ProfitNet Margin %
1.2b1.3b1.3b1.3b1.3b1.4b1.4b1.5b311m345m365m380m349m393m399m383mQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'2625.4%26.9%28.3%28.2%26.1%27.6%27.9%26.2%
▲▲▲▲▲▲▲▬

Sales grew about 19.5% over the last 8 quarters: customers keep spending more with this company.

Profit grew about 23.1% over the last 8 quarters: the business is keeping more of what it earns.

Why 100?
Pillar score: (2 + 2 + 2) = 6 of 6 points → 100
Debt-to-Equity0.1×StrongCurrent Ratio3.1×StrongInterest Coverage30.3×Strong
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↓ -47.7%Equity ↑ +59.5%D/E 0.1×
Total DebtEquityD/E
1.6b874m852m826m4.1b4.9b6.0b6.6b20232024202520260.4×0.2×0.1×0.1×

Borrowings fell about 47.7% over 4 years: the company is steadily getting safer.

Short-term assets vs bills, with Current Ratio

Current Assets ↑ +82.6%Current Liabilities ↑ +83.9%Current Ratio 3.1×
Current AssetsCurrent LiabilitiesCurrent Ratio
2.4b2.4b3.5b4.3b759m911m1.0b1.4b20232024202520263.1×2.6×3.4×3.1×
Why 75?
Pillar score: (0 + 2 + 2 + 2) = 6 of 8 points → 75
Dividend Quality1%Weak
Payout ratio: 23%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsGrowing & covers near-term debtStrong
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +160.5%Free CF ↑ +191.2%
Operating CFFree CF
693m1.4b1.8b1.8b559m1.3b1.7b1.6b2023202420252026

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash ↑ +544.7%Short-Term Debt ↑ +2,525.3%Total Debt ↓ -47.7%
CashShort-Term DebtTotal Debt
228m238m1.2b1.5b10m10m10m260m1.6b874m852m826m2023202420252026

Dividends per Share, with Yield

DPS (cents) ↑ +36.4%Yield % 1.1%
DPS (cents)Yield %
444448484853606017619221224020232024202520260.8%1.1%0.9%1.1%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 17?
Pillar score: (0 + 0 + 1) = 1 of 6 points → 17
P/E Ratio21.8×WeakP/B Ratio5×WeakPEG Ratio1.1Okay
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 269.43US$ 228.76US$ 188.09Oct '25Feb '26Jun '26Oct '26

The share price is down about 5.9% over the past year.

Why 92?
Pillar score: (2 + 2 + 2 + 2 + 1 + 2) = 11 of 12 points → 92
Earnings ConsistencySteadyStrongDebt Trend (4yr)FallingStrongShare Count Trend (4yr)-1%/yrStrongInventory vs Sales (4yr)-12 pp/yr vs salesStrongAsset Turnover Trend (4yr)+0.8%OkayQuarterly Consistency0 of 4 quarters downStrong
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +33.9%Inventory ↓ -5.2%Inv. % of Rev. 16.7%
RevenueInventoryInv. % of Rev.
4.2b4.7b5.1b5.7b998m822m928m946m202320242025202623.6%17.5%18%16.7%
Ranks #2 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79
#2ResMed (you)77
#3Steris75#4Dexcom73#5Insulet71#6Boston Scientific68

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDividend Payout RatioDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 5.7bUS$ 1.5bUS$ 1.8bUS$ 1.6bUS$ -177.2mUS$ 1.5bUS$ 825.9mUS$ 259.9mUS$ 6.6bUS$ 4.3bUS$ 1.4bUS$ 9.0bUS$ 2.4bUS$ 945.8mUS$ 240.0m23%27%0.1×3.1×-23%1%19.8×4.6×1.0
2025US$ 5.1bUS$ 1.4bUS$ 1.8bUS$ 1.7bUS$ -100.6mUS$ 1.2bUS$ 851.8mUS$ 9.9mUS$ 6.0bUS$ 3.5bUS$ 1.0bUS$ 8.2bUS$ 2.2bUS$ 927.7mUS$ 212.0m23%27%0.1×3.4×-22%1%26.5×6.2×1.2
2024US$ 4.7bUS$ 1.0bUS$ 1.4bUS$ 1.3bUS$ -114.9mUS$ 238.4mUS$ 873.9mUS$ 9.9mUS$ 4.9bUS$ 2.4bUS$ 910.7mUS$ 6.9bUS$ 2.0bUS$ 822.2mUS$ 192.0m21%22%0.2×2.6×30.3×28%1%27.0×5.7×0.9
2023US$ 4.2bUS$ 897.6mUS$ 693.3mUS$ 559.3mUS$ -134.0mUS$ 227.9mUS$ 1.6bUS$ 9.9mUS$ 4.1bUS$ 2.4bUS$ 758.5mUS$ 6.8bUS$ 2.6bUS$ 998.0mUS$ 176.0m22%21%0.4×3.1×24.3×29%1%34.7×7.5×2.7